IBB reached the target we forecasted on May 6 and at this stage it should have completed primary wave 5. It should now start a correction that can take it to new lows. The alternative scenario would be that we would see a minor correction to around 115 before trend to new highs. However, in both cases prices should follow the path to at least arounf the most...
IBB seems to have starting minor wave 5 up that could lead its price to the most probable target of 134.00. This sector should be be one of the good options to be in during the current market scenario. If prices crosses down 199.70, this analysis should be reviewed. FOLLOW SKYLINEPRO TO GET UPDATES.
I'm bull-ish on Novavax (see Related Idea). I think their approach to the COVID-19 vaccine is promising - their recombinant nanoparticle vaccine technology and Matrix-M adjuvant. They also have positive long-term prospects with their proprietary NanoFlu candidate. This is the big one to me. It's unclear whether COVID-19 becomes seasonal or not but influenza is...
Contextual immersion trading strategy idea. Athersys is a biotechnology company, focuses on the research and development activities in the field of regenerative medicine. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher than the supply. These and...
Contextual immersion trading strategy idea. NeuBase Therapeutics is a pre-clinical-stage biopharmaceutical company, focuses on the development of therapies to treat rare genetic diseases and cancers caused by mutant genes. The demand for shares of the company looks higher than the supply. These and other conditions can cause a rise in the share price in the...
Quote: "Bemcentinib has shown effect against SARS-CoV-2 (coronavirus) in animal models and has been selected as the first of six drugs to be fast-tracked in the new UK initiative (ACCORD) to enter a phase 2 study directly. Although there are many uncertainties around valuing this opportunity, we estimate the new indication adds NOK 21/share, with a new TP of NOK...
The lack of strength of the recent rally and the downward trend suggests a short-term test of support.
VBIV is breaking out of a symmetrical triangle on 15min within a much larger ascending triangle on 4hr which may be a continuation pattern off of the local price bottom. I expect to see $1.50 within next 3 trading days.
This IPO was just listed on FEB, 6th 2020 and will be killing it every earnings and has the potential to big a really big play in the market during these times. The chart I have posted is a 4HR time frame. Definitely one to add to your portfolio for awhile! I can see this being a GOLDEN GOOSE to get into early during these times! options plays are good on this one...
Contextual immersion trading strategy idea. InflaRx N.V., a clinical-stage biopharmaceutical company, discovers and develops inhibitors using C5a technology primarily in the United States and Europe. The share price rose after good earnings. I see some preconditions the share price will continue growing. The demand for shares of the company still looks higher...
TRIL has broken up from its wedge formation and has successfully backtested the breakout zone. Price retraced 61.8% of the first impulsive leg higher and the stock now appears to be getting ready for a HUGE RUN UP. Long from here.
AMEX:OGEN is going to rip into earnings then pull back right before then pop for 100% or more post earnings. Here are my price targets placed for the next week every few days starting with next Monday. DD: OGEN has *1 drug for Oral Mucosis just finished Phase 2 trial, FULL data will be release on earnings call and ironically at the same time they have $15...
Successful completion of the pivotal Phase 3 program for Sci-B-Vac®, on-track for submission of regulatory approval applications in the U.S., Europe, and Canada expected to begin in Q4 2020 Announcement of pan-coronavirus vaccine candidate targeting COVID-19, SARS, and MERS – human clinical study material expected to be available in Q4 2020 Expanded immunologic,...
What is XBi? XBI provides exposure to one of the broadest portfolios among US biotech ETFs. The fund equal-weights its portfolio, which in turn emphasizes small- and micro-caps and greatly reduces single-name risk. Thus, the weighted-average market cap is much smaller than some competitors. Unlike other funds in this segment, XBI is a pure biotech play, with...
About Horizon Therapeutics Horizon Therapeutics(ticker: HZNP) is a biopharmaceutical company that focuses on researching, developing, and commercializing medicines that address unmet treatment needs for rare and rheumatic diseases in the United States and internationally. It has collaboration agreements with Alliance for Lupus Research, Syneos Health, Inc., and...
Teva's earnings May 7th - www.sec.gov Weekly chart is flashing buy signals with the 50SMA Crossing back under the price. Unknowns: COVID-19 impact on TEVA earnings Decision - Wait until after earnings to get in, still to many unknowns. The reason I like TEVA : Possible Turn-around play, looking for teva to turn net-loss to net-profit in the coming years if...